License & Collaborative Revenue was Protagonist Therapeutics’s largest revenue line in fiscal 2020, bringing in $27.10M of $28.60M (95%).
| Products and Services | FY 2020 |
|---|---|
| License & Collaborative Revenue | $27.10M |
| Additional Services | $1.50M |
| Total | $28.60M |
Protagonist Therapeutics brought in $28.60M from its two revenue lines in fiscal 2020, the year ended December 31, 2020. License & Collaborative Revenue was the largest at $27.10M (94.8%), ahead of Additional Services at $1.50M (5.2%).
Iconic Total Phase was Protagonist Therapeutics’s largest revenue line in fiscal 2023, bringing in $50.00M of $60.00M (83%).
| Research And Development Arrangement Contract To Perform For Others By Type | FY 2023 |
|---|---|
| Iconic Total Phase | $50.00M |
| Anthem Phase Two B | $10.00M |
| Total | $60.00M |
Protagonist Therapeutics brought in $60.00M from its two revenue lines in fiscal 2023, the year ended December 31, 2023. Iconic Total Phase was the largest at $50.00M (83.3%), ahead of Anthem Phase Two B at $10.00M (16.7%).
Protagonist Therapeutics (PTGX) reports its revenue by products and services and by research and development arrangement contract to perform for others by type. In fiscal 2020, License & Collaborative Revenue was its largest revenue line, bringing in $27.10M (94.8% of the total), followed by Additional Services at $1.50M (5.2%).
License & Collaborative Revenue was Protagonist Therapeutics' largest revenue line in fiscal 2020, bringing in $27.10M, or 94.8% of the $28.60M total across its two revenue lines.
Every figure comes from Protagonist Therapeutics' annual financial filings, as reported. Each line keeps the name Protagonist Therapeutics gives it, and years follow its fiscal calendar.
Protagonist Therapeutics' revenue by products and services goes back to fiscal 2020, with figures through fiscal 2020. The latest four fiscal years are free to view, and the full history is available with a Business Quant subscription.